- Anthraquinone compound and its preparation method and medical use (by machine translation)
-
The invention relates to a anthraquinone compound and its preparation method and medical use, cheap and easy to get to the isophthalic acid as the starting material, through the bromo, hydrolysis, esterification of the obtained intermediate with 2 - bromo - 5 - methoxy acyl chloride condensation, condensation product after hydrolysis, loop, debromination reduction to obtain the target product 1, 5 - dihydroxy - 3 - carboxyl - 9, 10 - anthraquinone. The reaction of the invention cheap, low cost, simple operation, high yield. Anti-tumor activity study results display, artificial synthesis of 1, 5 - dihydroxy - 3 - carboxyl - 9, 10 - anthraquinone has better anti-tumor activity. (by machine translation)
- -
-
Paragraph 0006; 0010
(2017/08/30)
-
- Inclusion complex containing epoxy resin composition for semiconductor encapsulation
-
The invention is an epoxy resin composition for sealing a semiconductor, including (A) an epoxy resin and (B) a clathrate complex. The clathrate complex is one of (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II): wherein R2 represents a hydrogen atom, C1-C10 alkyl group, phenyl group, benzyl group or cyanoethyl group, and R3 to R5 represent a hydrogen atom, nitro group, halogen atom, C1-C20 alkyl group, phenyl group, benzyl group, hydroxymethyl group or C1-C20 acyl group. The composition has improved storage stability, retains flowability when sealing, and achieves an effective curing rate applicable for sealing delicate semiconductors.
- -
-
-
- COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
-
The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract
- -
-
Page/Page column 317
(2010/08/04)
-
- Naaladase inhibitors for treating retinal disorders and glaucoma
-
The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
- -
-
-
- Nanoscale faceted polyhedra
-
The subject invention pertains to nanoscale polyhedron-shaped molecules having molecular building blocks connected at their vertices. The subject invention also concerns methods of producing nanoscale polyhedrons utilizing a self-assembly reaction. The resultant molecules are faceted polyhedra that are porous, chemically robust, contain chemically accessible sites on their facets, and which are neutral and soluble in common laboratory solvents. The nanoscale polyhedrons can exhibit additional desirable physical properties, such as ferromagnetic properties.
- -
-
-
- Naaladase inhibitors for treating amyotrophic lateral sclerosis
-
The present invention relates to pharmaceutical compositions and methods for treating amyotrophic lateral sclerosis using NAALADase inhibitors.
- -
-
-
- Benzenedicarboxylic acid derivatives
-
New benzenedicarboxylic acid derivative compounds; pharmaceutical compositions, diagnostic methods, and diagnstic kits that include those compounds; and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-β activity, inhibiting angiogenesis, and treating glutamate abnormalities, neutopathy, pain, compulsive disorders, prostate diseases, cancers, and glaucoma.
- -
-
-
- A new route for the preparation of 5-hydroxyisophthalic acid
-
A new, simple and practical, two-stage process for the preparation of 5-hydroxyisophthalic acid (5-HIPA) from isophthalic acid is described. In the first stage, isophthalic acid is brominated by bromine in oleum, in the presence of an iodine catalyst, to give crude 5-bromoisophthalic acid (5-BIPA). In the second stage the crude 5-BIPA is hydrolyzed with aqueous NaOH, in the presence of a copper catalyst, to give crude 5-HIPA, with a purity of ca. 98%. Both stages of the process were optimized. A single crystallization of the crude 5-HIPA from water gives the product in a purity of more than 99%. The overall yield of pure 5-HIPA is 65-70%.
- Gelmont, Mark,Oren, Jakob
-
p. 591 - 596
(2013/09/06)
-
